Migraine

CGRP receptor antagonist

EVOLVE 1,2

PROMISE 1

ACHIEVE II

Ubrogepant (Ubrelvy) beneficial in Acute Treatment of Migraine

Rimegepant  (Nurtec ODT)

Above two are oral

Four parenteral CGRP antagonists,

erenumab (Aimovig),

fremanezumab (Ajovy),

galcanezumab (Emgality),

eptinezumab (Vyepti),

are approved for prevention of migraine